Longas Technologies Pty

Longas has developed Morphoseq™, a disruptive technology designed to dramatically improve the performance of industry-standard NGS platforms, by increasing effective read lengths, with benefits in accuracy and cost efficiency. Morphoseq effectively converts short read sequencers into ‘virtual long read’ sequencers, enabling finished-quality genome assemblies with high accuracy, including resolution of difficult-to-assemble genomic regions. Founded in 2015, and operating in stealth mode until its public launch in May 2019, the Company is a spin out from the ithree institute at the University of Technology Sydney (UTS), initially based on research led by Professor Aaron Darling, a world-leading computational biologist and co-founders Professor Ian Charles and Dr Catherine Burke. The Company has an extensive portfolio of international patent filings covering Morphoseq. Located in Sydney Australia, Longas is headed by renowned NGS leader, Nick McCooke and is funded by Australia’s Medical Research Commercialisation Fund (MRCF) and investment from the Company’s founders and directors. Longas’ business model is to partner with industry leaders to support the commercial development of its technology. For further information please visit www.longastech.com Follow us on Twitter: @Longastech @Morphoseq